Senate health committee narrows pharmacy compounding labeling rules after stakeholder concerns

BOISE, Idaho — The Senate Health and Welfare Committee on Wednesday approved a rewrite of the Idaho State Board of Pharmacy’s rule chapter while removing three subsections governing distribution labeling for compounded products, after testimony and late stakeholder outreach raised questions about how state rules would interact with a still-draft federal Food and Drug Administration guidance.

The committee voted to let a set of temporary pharmacy rules expire without action and then approved the board’s pending rule docket (IDAPA 24.36.01 — pending docket 24-3601-2402) with the committee’s amendment striking subsections listed as 214 E i and ii. Senator Lenny offered the successful substitute motion to remove those subsections; the motion passed on a committee roll call, with the chair announcing the motion passed and later the committee recording the vote as seven in favor and two opposed.

The changes come after the Idaho State Board of Pharmacy completed a ZBR (zero-based regulation) rewrite that removed duplicative statutory language and reorganized the chapter into sections on legal authority, scope, definitions, licensure, practice standards, discipline, fees, compounding and prescription drug monitoring. Nikki Chopsky, bureau chief of health professions for the Division of Occupational and Professional Licenses and executive officer for the Idaho State Board of Pharmacy, told the committee the board had held multiple public meetings and included representatives of both state pharmacy associations and individual…